INTRODUCTION
Colorectal cancer is the third most common cancer among U.S women, 63,610 new cases were estimated to have occurred in 2015. 1 Older women, ages 50-70, have a considerably higher risk of developing colorectal cancer as compared to younger women. 1 Antidepressant (AD) use is also common among older women, with 23% of women ages 40-59 and 18.6% of women ages 60 and over taking ADs according to the National Health and Nutrition Examination Survey (2008). 2 Among those treated with ADs, selective serotonin reuptake inhibitors (SSRIs) are the most common, whereas tricyclic antidepressants (TCAs) and other antidepressants have become less common, since 1995. 3 Roughly 78% of ADs are prescribed for depression, however other uses of ADs include mood disorders, anxiety, and chronic pain. 4, 5 Compared to healthy individuals, women with depression have high levels of inflammatory markers, which may lead to a 40% increased risk of colorectal cancer. 6, 7 Furthermore, women with depression are more likely to have risk factors of colorectal cancer such as higher body mass index (BMI), poor diet (i.e. high fat, low fiber diets), smoking, drinking, and physical inactivity. 6, 7 This is important as depression is highly related to AD use and studies suggest that depression may lead to inflammatory and behavioral risk factors for colorectal cancer; thus, to determine the true effects of AD use on risk of colorectal cancer we must consider the effects of depression.
Whether AD use influences colorectal cancer remains unclear. Several studies have reported decreased risk of colorectal cancer among regular AD users compared to non-users. [8] [9] [10] [11] [12] When SSRIs and TCAs were examined separately, three out of five studies observed strong inverse associations between SSRIs and risk of colorectal cancer. 8, 9, 12 A significant reduction in risk of colorectal cancer was observed among SSRI users taking a high cumulative dose (>0.01 mol) within the five years before diagnosis (OR 0.69, 95% CI: 0.50-0.96) 12 and among regular users of SSRIs (taking SSRIs consecutively for three months) (OR 0.55, 95% CI: 0.35-0.88) when compared with non-users. 9 Another study observed a non-statistically significant reduced risk among SSRI users, specifically among those using SSRIs for less than 2 years. 8 Conversely, two studies found no association between SSRIs and risk of colorectal cancer when considering different intensities and durations of use. 10, 11 Studies which examined the effects of TCA use on risk of colorectal cancer were similarly unclear. A non-significant reduction of colorectal cancer was observed among regular TCA users (OR 0.77, 95% CI: 0.52-1.16), 9 regardless of duration of use. 8, 9 Conversely, a record linkage study that looked at non-SSRI use, much of which is likely TCAs, found a nonsignificant increased risk of colon cancer within the highest category (1460 mg average maintenance dose per day) as compared to users within the lowest category (RR 2.19, 95% CI:
0.85-5.66 and RR 2.03, 95% CI: 0.83-4.96 respectively). 11 Furthermore, a separate case-control study found no association between TCAs and colorectal cancer when considering various intensities and duration of use. 10 Laboratory studies support a possible protective effect of SSRIs on colorectal cancer.
Elevated levels of serotonin have been hypothesized to play a role in colorectal cancer, promoting cell division of adenocarcinomas of the large intestine. SSRIs act as an antagonist, inhibiting the reuptake of serotonin, reducing the mitotic rate of tumor cells within the colon. 12, 13 Laboratory studies examining the effects of TCAs on colorectal cancer have been less clear, as in vitro studies of the effects of TCAs on human carcinoma cell lines have shown evidence to support both an increase and decrease in the risk of colorectal cancer. 18 for the clinical trial were invited to join the observational study. The observational study (N=93,676) 18 examined the relationship between lifestyles, health and risk factors, and specific disease outcomes. The medical history and health habits of the women in this arm were followed through 2005.
Eligibility criteria that was the same for both arms of the WHI was defined as being between the ages of 50-79, postmenopausal, and planning to reside within the study area for at least three years after enrollment. If participants had a pre-existing medical condition that was predictive of a survival time less than three years, a condition that could interfere with consistency or adherence, or if they were currently participating in another randomized control trial they were excluded from both the CT and OS. 18 Exclusion criteria for this analysis included missing information on AD use (n=2), and/or missing information on follow-up time (n=691).
No participants had missing information on diagnosis of colorectal, colon, or rectal cancers.
Further, participants were excluded from our analysis if they had a previous history of any cancer 
Statistical Analysis
Participants were categorized by AD use (AD user, non-AD user) at baseline to examine the distribution of covariates between participants (Table 1) . Additionally we examined the distribution of AD drug class (Table 2 ) and colorectal cancers (Table 3) by AD use. To examine the distribution of drug class, covariates, and colorectal cancers by AD use, we used chi square tests and t-tests as appropriate.
We used multivariable Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) of the association between AD use and time to colorectal cancer diagnosis while adjusting for potential confounders. In these analyses, women were followed from enrollment through 2005, contributing person-time to the analysis until diagnosis of colorectal, colon, or rectal cancers, death, loss-to follow-up, or the end of the study/ administrative censor date defined as the participants last available date, whichever happened first. We separately examined the relationship between AD use and the risks of colon cancer and rectal cancer, and evaluated the associations between subgroups of ADs most commonly used in this cohort (SSRIs, TCAs, and other ADs) and colorectal cancer. We additionally examined the effects of duration of AD use, including duration of SSRIs, TCAs, and other ADs. Among AD users, the most common treatment was SSRIs (51.1%), followed by TCAs (40.7%), and other antidepressants (15.1%) ( Table 2) . Additionally, some women reported use of more than one AD, with 303 taking TCAs and SSRIs, 312 taking SSRIs and some other AD, 81
taking TCAs and some other AD, and 7 women taking all three (data not shown).
During the study follow-up period, 2,580 women were diagnosed with colorectal cancer (Table 3) No significant association was observed between AD use with risk of rectal cancer (Table 6 ).
We also explored how AD use affected colorectal cancer risk among women with and without depressive symptoms ( 
DISCUSSION
In this prospective study of postmenopausal women, we observed a statistically significant 32% reduced risk of colon cancer among TCA users, though this effect was limited to those using TCAs for less than two years. A similar decreased risk of rectal cancer was observed among TCA users using for less than two years, however results were limited by small numbers and were not significant. Overall, we found no compelling evidence of an association between total AD use, SSRIs, or other ADs on the risk of colorectal, colon, or rectal cancers specifically.
Prior evidence of the relationship between TCAs and colorectal cancer is contradictory.
Some epidemiological studies of TCA use found non-significant reductions of colorectal cancer, 8, 9 while others observed no association. 10, 12 A case-control study which enrolled 649 cases from an integrated healthcare delivery system (N=1,305), observed a reduced risk of colorectal cancer among TCA users (OR 0.7, 95% CI: 0.5-1.1), and those using the drug for less than two years (OR 0.6 95% CI: 0.3-1.0). 8 Additionally, in another case control study, a non-significant reduced risk of colon cancer among TCA users (OR 0.81, 95% CI: 0.51-1.29) was observed (N=10,011). 9 Conversely, two studies found no association between TCA use and risk of colorectal cancer. 10, 12 Differences between our analysis and previous studies may be due to their smaller sample size, which limited their ability to detect an association between TCA use and risk of colorectal cancer. 8, 9 Additionally, we were able to control for important potential confounders, (i.e. depression, colonoscopy history, and polyp removal) which may have enhanced our ability to see a true effect. Limited control of confounding factors, particularly depression, may have reduced the ability of previous studies to observe the independent effect of TCA use on colorectal cancer risk. [8] [9] [10] [11] [12] Further, our observation of an inverse association between colorectal cancer and TCA use was restricted to current users, and was not observed among longer term users, which raises some concern about whether the association is real. Prior studies measured AD use through pharmacy records or databases. [8] [9] [10] [11] [12] In the WHI, however, women were asked to bring in current medications to their clinical visit, and self-report duration of use.
While this has the advantage of capturing current use, it may not reliably capture past use or adherence. Pharmacy records are similarly limited in this fashion as participants could have filled prescriptions and not taken prescribed ADs, or they could have been taking them inconsistently.
This misclassification of use could have led in part to the null results observed by previous studies 10, 12 and the null findings of studies which looked at use for greater than 2-3 years. 8, 9 Additionally, misclassification of use could have attenuated our ability to detect a true association between AD use and risk of colorectal cancer, particularly when considering duration of use greater than two years, and may in part account for our null findings in this group.
In contrast to our null association between SSRI use and colorectal cancer, some previous studies observed a reduced risk of colorectal cancer among SSRI users. 8 contributing to their null results. As both previous studies and our current analysis were limited by misclassification of use more information is needed to verify our results and explore the true effects of SSRIs.
An important limitation of previous studies is that none have controlled for the effects of depression in the relationship between AD use and colorectal cancer. [8] [9] [10] [11] [12] As mentioned earlier about 78% of AD users are prescribed ADs for depression. 5 Compared to healthy individuals, those with depression have higher levels of inflammatory markers, such as C-reactive protein, pro-inflammatory cytokines, and raised serum levels of interleukin-6 (IL6), interleukin-1 beta (IL1b), and tumor necrosis factor alpha (TNFa) potentially increasing risk of cancer. 6, 7 Prior studies support a relationship between depression and increased risk of overall cancer. [14] [15] [16] [17] Those that looked at colorectal cancer observed an increased risk of colorectal cancer. To determine the independent effects of depression and AD use on risk of colorectal cancer. To our knowledge, this is the first study to examine the separate and combined relationship between depressive symptoms and AD use and colorectal cancer risk. We observed an increased colorectal cancer risk among women experiencing depressive symptoms without AD use (HR 1.21, 95% CI: 1.05-1.4) compared to women with neither depressive symptoms nor AD use. This is important as it corroborates that women with depression may have an increased risk of colorectal cancer particularly among those not using AD medications.
The biological mechanism through which TCA may act is unclear. In vitro studies of the effects of TCAs on human carcinoma cell lines have shown evidence to support both an increase and decrease in the risk of colorectal cancer. 12 TCAs were examined in an in vitro model of Human HT29 colon adenocarcinoma cells using three TCA drugs, imipramine, desipramine, and amitriptyline. 30 All three of these TCA drugs exhibited cytotoxic effects acting through a nonmitchondrial pathway associated with cell cycle progression, suggesting this effect is specific to malignant colorectal tumors. 30 In order for this to occur it is necessary for the drug to reach cytotoxic levels within the cell, ~10µm. It still remains to be seen if oral use of TCA drugs can achieve cytotoxic levels in colorectal colon and rectal tissues; 30 however, our results of a possible protective association may indicate that cytotoxic levels can be reached in human subjects. Conversely, in rat models of colorectal cancer using the TCA, desipramine, serum levels of norepinephrine increased the proliferation of colon epithelial cells, indicating a carcinogenic effect. 31 These results show that TCA composition and type may matter in terms of the carcinogenic or cytotoxic effect. 12 As information on TCA composition, type, and genotoxicity was unavailable, our study is limited in its capability to determine the protective effects of specific TCA drugs, but is indicative of a possible cytotoxic mechanism of overall TCA use. Although our results show no association between SSRI use and risk of colorectal cancer, laboratory studies support protective effects of SSRIs on colorectal cancer. One such study observed reduced tumor cell growth after administering SSRIs to mice xenografted with human colorectal carcinomas compared to controls, indicating possible cytotoxic effect of SSRIs. 8 In human colorectal cancer cell line a similar effect was observed when treated with SSRIs. 8 Serotonin levels have been hypothesized to play a role in colon cancer, as serotonin levels promote cell division of adenocarcinomas of the large intestine. SSRIs inhibit the uptake of serotonin, reducing the mitotic rate of tumor cells within the colon. 12, 13 Limitations of this study primarily relate to our measurement of AD use and depressive symptoms and our power. Null results observed with SSRI use and risk of colorectal cancer may relate to the fact that SSRI drugs were new to the market at the time of WHI baseline. In general, TCA use to treat depression was greater prior to 1995 and SSRI use for treatment of depression was greater after 1995. As our analysis only assessed AD use at baseline we lack the ability to see if a recency of SSRI use may have led to our null results. Additionally, we had small numbers to detect an association between duration of use and risk of colorectal cancer for TCAs and other ADs. Further we had small numbers of AD users who developed rectal cancer which limited our ability to detect an effect of AD use on risk of rectal cancer. To ascertain current medication use, women in the WHI brought in pill bottles of current medications and supplements. This is advantageous as it is an accurate way to measure current use; however, if women failed to bring in their pill bottles we may have some misclassification and numbers may be underestimated. Furthermore, this method lacks the ability to capture specific information on chemical make-up, past use, dose, and intensity. Although names of the specific ADs were available and may give some information on aspects of chemical make-up, this information was not used for this analysis, and as such we were unable to account for any effects. Additionally, duration of use was based on self-report, and as such are subject to some recall error, and does not reliably capture past use or adherence. Therefore, our results for duration of use should be interpreted with caution. Depressive symptoms were measured according to a self-administered questionnaire from which a CES-D score was calculated. Although this method has high levels of sensitivity and specificity, it differs from the gold standard of a clinical diagnosis. Thus, the inability to accurately control for depression lead to residual confounding which may have attenuated the true relationship between AD use and risk of colorectal cancer.
Strengths of our study include its prospective design, large sample size, and comprehensive data on potential confounders. Data for this study contained extensive information on depressive symptoms, history of a previous colonoscopy, diet, and BMI, which had not been previously controlled for, this limited potential confounding within our study.
Further, as mentioned previously, the methods use in this study showed increased accuracy of actual, current AD use.
CONCLUSION
In summary, our results support a slightly suggestive inverse association between TCA use and risk of colorectal cancer. These findings contribute to a better understanding of the safety of AD use and provide some reassurance, as they suggest that AD use does not increase risk of colorectal cancer. Given the high prevalence of depression and AD use, future work is needed to understand and verify these associations, and to explore the effects of SSRIs with more recent data is warranted. 
